Account for estrogen effect on cortisol when assessing adrenal reserve
STEP 1 — Gather Information
Collect patient's estrogen status (type, route, dose), total serum cortisol level, time of draw, and note if estrogen is oral (which increases CBG) vs transdermal (no effect) or pregnancy/OCP.
STEP 2 — Rule In / Rule Out
If the patient is on oral estrogen (or other estrogen known to increase CBG), proceed to Step 3; otherwise, interpret total cortisol using standard reference ranges and proceed to Step 4.
STEP 3 — Classify or Stratify
Measure free cortisol or 24-hour urinary free cortisol to assess true adrenal cortical activity.
STEP 4 — Decide
Base decisions on adrenal reserve or HC adequacy on free cortisol or urinary cortisol results; do not adjust HC dose based solely on elevated total cortisol in estrogen-exposed patients.
Clinical Guardrails / Mimics / Pitfalls
- Do not assume elevated total cortisol indicates Cushing's syndrome or glucocorticoid over-replacement in estrogen-treated patients.
- Avoid reducing hydrocortisone dose based solely on high total cortisol when CBG is elevated.
- Remember that transdermal estrogen does not increase CBG; only oral estrogen (and pregnancy) produce this effect.
- Consider that free cortisol or urinary cortisol reflects bioactive fraction and is unaffected by CBG changes.
Concrete Clinical Example
A 45-year-old woman on oral estradiol 2 mg daily for hypopituitarism has a morning total cortisol of 22 µg/dL (above normal range). Her free cortisol is normal. She is on stable hydrocortisone 15 mg daily. Decision: maintain current hydrocortisone dose; the elevated total cortisol is due to CBG increase from oral estrogen.
Source: Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, doi:10.1210/jc.2016-2118